Danilon Ekvidos (Danilon Equidos), 1,5 g
Danilon Equidos, 1.5 g
Pharmaceutical form
Yellow and odorless granules.
Pharmacological properties
Pharmacotherapeutic group: anti-inflammatory and antirheumatic drugs, non-steroids ATC verification code: QM01AA90 Pharmacodynamic properties Suxibuzone is a non-steroidal anti-inflammatory drug (NSAID) synthetically derived from pyrazolone with anti-inflammatory, antipyretic and analgesic properties with low ulcerative properties. When mixed with concentrate feed, the product has been shown to be acceptable for horses. Its mechanism of action is based on the inhibition of cyclooxygenase (an enzyme that catalyzes the synthesis of prostaglandins, prostacyclins and thromboxanes from arachidonic acid). Therapeutic effects are mainly associated with inhibition of the biosynthesis of prostaglandins, which act as peripheral mediators of pain and induce the synthesis of endogenous pyrogens and mediators in the inflammatory process. It also inhibits platelet aggregation. The therapeutic effect of suxibuzone depends entirely on the activity of its active metabolites. Shown strong anti-inflammatory activity for phenylbutazone and oxyphenbutazone. The third metabolite, g-hydroxyphenbutazone, is considered pharmacologically inactive. After oral administration, suxibuzone is readily absorbed, and most of it is metabolized by the hepatic microsomal system, producing phenylbutazone, oxyphenbutazone, and g-hydroxyphenylbutazone. No unchanged parent compound can be detected in plasma following oral administration of equine succinusone. These active metabolites have a high affinity for plasma proteins and are eliminated mainly in the urine as glucuronide conjugates, but also in a small percentage in the faeces. Less than 1% is eliminated by saliva and milk. After administration of a single oral dose of 6.25 mg / kg of the parent compound, phenylbutazone reaches its maximum plasma concentration (10 μg / ml) 4-5 hours after administration with a half-life of 5-6 hours. Oxyphenbutazone reaches a maximum (2.1 μg / ml) 15 hours after administration. As with other NSAIDs, the duration of the clinical response is much longer than the plasma half-life. Significant concentrations of both active metabolites are found in synovial fluid for at least 24 hours after administration. 1 μg / ml) 15 hours after administration. As with other NSAIDs, the duration of the clinical response is much longer than the plasma half-life. Significant concentrations of both active metabolites are found in synovial fluid for at least 24 hours after administration. 1 μg / ml) 15 hours after administration. As with other NSAIDs, the duration of the clinical response is much longer than the plasma half-life. Significant concentrations of both active metabolites are found in synovial fluid for at least 24 hours after administration.
Indications for use
Treating pain and inflammation associated with equine musculoskeletal conditions such as osteoarthritis, bursitis, laminitis and soft tissue inflammation.
Contraindications
Do not administer to animals with renal, hepatic or cardiac problems; where there is the possibility of gastrointestinal ulceration or bleeding, or when there is evidence of dyscrasia or hypersensitivity to the product. Avoid use in dehydrated, hypovolemic, or hypotensive animals as there is an increased risk of renal failure.
Special warnings
Do not accept horses prior to entering the competition. During treatment for very young animals (less than 12 weeks), when their liver or kidney function may not develop fully, or in older animals that may have these impairments, or in ponies, additional risks may be involved. In these cases, doses must be accurately calculated and patients carefully monitored. Do not limit water intake during treatment. Avoid use in any dehydrated, hypovolemic, or hypotensive animals as there may be an increased risk of renal failure. NSAIDs can induce inhibition of phagocytosis and, therefore, in the treatment of inflammatory conditions associated with bacterial infections, appropriate antimicrobial therapy should be instigated.
Special precautions for use in animals
Do not limit water intake during treatment. Use on very young or older animals and ponies may have additional risks. Adjust dose according to body weight and monitor clinical response closely. Do not exceed the stated dose or duration of treatment. Dosage should be kept to a minimum to relieve symptoms.
Special precautions to be taken by the person handling the animal product
Wear suitable gloves. Wash your hands after use. Use in a well ventilated area. Avoid inhaling dust when opening the sachet and mixing with feed. In case of accidental contact with eyes, rinse immediately with plenty of clean water. If accidentally swallowed, seek medical advice immediately and show this label to a doctor.
Adverse Reactions (Frequency and Severity)
After prolonged use or at high doses, gastrointestinal changes may occur. Blood disorders and renal changes may occasionally occur, especially in animals with limited access to water.
Use during pregnancy and lactation
No studies have been conducted on horses for safe use during pregnancy and lactation.
Interaction with other veterinary medicinal products
Suxibuzone and its metabolites can be strongly bound to plasma proteins and compete with other highly bound drugs, for example, sulfonamides, warfarin; or it may itself be biased to cause an increase in unrelated pharmacologically active concentrations that can lead to toxic effects. Drug compatibility should be carefully monitored if additional therapy is required. The simultaneous use of potentially nephrotoxic drugs should be avoided.
Dosage
Horses
For a horse weighing 480 kg, the contents of two sachets should be administered twice daily (equivalent to 12.5 mg suxibuzone / kg / day) for 2 days followed by 1 sachet twice daily (6.25 mg suxibuzone / kg / day) for 3 days. Thereafter, 1 sachet daily (3.1 mg suxibuzone / kg / day) or on alternate days or the minimum dose required for a satisfactory clinical response.
Pony
Ponies should only receive half the recommended dose for horses. For a bodyweight of 240 kg, the contents of 1 sachet should be administered daily (equivalent to 6.25 mg suxibuzone / kg / day) for 2 days followed by a daily sachet of 1/2 sachet (3.1 mg suxibuzone / kg / day) for 3 days or 1 sachet on alternate days. Then, reduce the dose to the minimum dose necessary for a satisfactory clinical response. Use a measuring bucket for injecting less than one sachet. One full scoop contains 5 g of granules (equivalent to 1/2 sachet) and up to the green line contains 2.5 g of granules (equivalent to 1/4 sachet). If clinical response does not appear after 4-5 days, discontinue treatment and reconsider the diagnosis.
Overdose (symptoms, emergency procedures, antidotes)
In case of accidental continuous overdose, the following symptoms may occur:
Thirst, depression, anorexia, and weight loss
Gastrointestinal upset (irritation, ulcers, diarrhea, and blood in feces)
Altered blood and hemorrhage profiles
Hypoproteinemia with ventral edema causes hemoconcentration, hypovolemic shock, and circulation.
Renal failure and fluid retention.
If signs of intolerance appear, discontinue treatment and establish symptomatic therapy. Slow intravenous perfusion of sodium bicarbonate solution, which leads to alkalinization of the urine, increases the clearance of the product.
Shelf life of packaged veterinary medicinal product: 4 years
Shelf life after the first opening of the sachet: 7 days.